Background
==========

Gadolinium-enhanced CMR can be a useful adjunct in the diagnosis and assessment of acute myocardial infarction (AMI). However, gadolinium contrast is contraindicated in severe renal impairment. Alternative, non-gadolinium contrast agents for AMI assessment and contrast-enhanced CMR in general would be of substantial clinical importance. Ferumoxytol, an intravenous iron-supplementation drug, was approved in 2009 by the FDA for treatment of iron-deficiency anemia in patients with chronic kidney disease, and is known to have T1 shortening properties. The utility of T1-weighted ferumoxytol-enhanced CMR for detecting AMI has not been previously evaluated.

Methods
=======

Six canines underwent acute LAD occlusion (70-minutes) with reperfusion. In-vivo CMR was performed four days post-MI on a 3.0T scanner in five animals (one animal died prior to acquisition of images). Clinically available Ferumoxytol (30mg Fe/ml) was administered to provide 5 mg Fe/kg body weight. Short-axis T1-maps were acquired using a single-shot inversion-recovery, gradient-echo sequence with \>20 inversion times ranging from 100-3000 ms. Acquisitions were separated by \>10-second delay to allow full recovery of magnetization, and T1 times were determined by standard 3-parameter iterative curve-fitting. T1 maps were acquired serially at multiple time-points (5-8) following Ferumoxytol-injection (range 1-24 hours). Following imaging the hearts were removed for histopathologic analysis and the presence, location, and extent of AMI was validated by 2, 3, 5-triphenyl-tetrazolium chloride (TTC) staining.

Results
=======

All five animals had AMI verified by pathology, and mean infarct size was 12.7% (range 2.6-16.8%) of LV mass. Ferumoxytol-kinetics of AMI was complex following two patterns (Figure [1](#F1){ref-type="fig"}, top). Pattern one (n=3) demonstrated an early restriction of Ferumoxytol uptake in AMI regions (approx. 0-2 hrs post Ferumoxytol) compared with normal myocardium followed later by increased uptake in AMI relative to normal (approx. 2-6 hrs post), and finally washout of Ferumoxytol in both AMI and normal myocardium (24 hrs post). Pattern two (n=2) demonstrated reduced Ferumoxytol uptake compared with normal myocardium throughout all time points (Figure [1](#F1){ref-type="fig"}, bottom). The absolute difference in T1 between normal myocardium and AMI over time averaged for the five animals is shown in Figure [2](#F2){ref-type="fig"}. In 20 of 27 time-points (74%), the absolute T1-difference was \>100ms, which was sufficient to visualize AMI on routine inversion-recovery CMR.

![Difference between normal minus infarcted myocardium. Pattern one shows the uptake of ferumoxytol contrast. At time 30 min there is non-uptake of contrast - infarct appears black or hypo-intense. At time 5 hours there is uptake of contrast - infarct appears whit or hyper-intense. At 24 hours the contrast has washed out of the infarct.](1532-429X-15-S1-P173-1){#F1}

![Absolute Difference in T1 between Normal and Infarcted Myocardium (ms) over Time after administration of Ferumoxytol contrast.](1532-429X-15-S1-P173-2){#F2}

Conclusions
===========

Ferumoxytol kinetics in AMI are complex and may reflect either reduced or increased contrast uptake depending on time post contrast administration. However, AMI can consistently be detected by Ferumoxytol-enhanced CMR given positive absolute differences in T1.
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